Tango Therapeutics Ownership

TNGX Stock  USD 10.33  0.30  2.99%   
Tango Therapeutics shows a total of 134.59 Million outstanding shares. The majority of Tango Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tango Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tango Therapeutics. Please pay attention to any change in the institutional holdings of Tango Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that roughly four million five hundred fourty-nine thousand two hundred seventy-seven invesors are currently shorting Tango Therapeutics expressing very little confidence in its future performance.
 
Shares in Circulation  
First Issued
2020-03-31
Previous Quarter
110.5 M
Current Value
111 M
Avarage Shares Outstanding
81.9 M
Quarterly Volatility
32.7 M
 
Covid
Some institutional investors establish a significant position in stocks such as Tango Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Tango Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tango Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

Tango Stock Ownership Analysis

About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.91. Tango Therapeutics had not issued any dividends in recent years. Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts. Tango Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people. To find out more about Tango Therapeutics contact Barbara MD at 857 320 4900 or learn more at https://www.tangotx.com.
Besides selling stocks to institutional investors, Tango Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tango Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tango Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Tango Therapeutics Quarterly Liabilities And Stockholders Equity

210.14 Million

Tango Therapeutics Insider Trades History

About 5.0% of Tango Therapeutics are currently held by insiders. Unlike Tango Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tango Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tango Therapeutics' insider trades
 
Covid

Tango Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Tango Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tango Therapeutics backward and forwards among themselves. Tango Therapeutics' institutional investor refers to the entity that pools money to purchase Tango Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Siren, L.l.c.2025-06-30
3.4 M
Balyasny Asset Management Llc2025-06-30
3.2 M
T. Rowe Price Investment Management,inc.2025-06-30
3.2 M
Bain Capital Life Sciences Investors, Llc2025-06-30
2.7 M
Ra Capital Management, Llc2025-06-30
M
Millennium Management Llc2025-06-30
1.8 M
Geode Capital Management, Llc2025-06-30
1.8 M
Marshall Wace Asset Management Ltd2025-06-30
1.7 M
Commodore Capital Lp2025-06-30
1.5 M
Trv Gp Iv, Llc2025-06-30
16.9 M
Tcg Crossover Management, Llc2025-06-30
10.7 M
Note, although Tango Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tango Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tango Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tango Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tango Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Third Rock Ventures Iv, L.p. over two months ago
Disposition of 500000 shares by Third Rock Ventures Iv, L.p. of Tango Therapeutics at 8.017 subject to Rule 16b-3
 
Third Rock Ventures Iv, L.p. over two months ago
Disposition of 363541 shares by Third Rock Ventures Iv, L.p. of Tango Therapeutics at 7.04 subject to Rule 16b-3
 
Third Rock Ventures Iv, L.p. over two months ago
Disposition of 86459 shares by Third Rock Ventures Iv, L.p. of Tango Therapeutics at 7.0395 subject to Rule 16b-3
 
Third Rock Ventures Iv, L.p. over three months ago
Disposition of 302194 shares by Third Rock Ventures Iv, L.p. of Tango Therapeutics at 7.0 subject to Rule 16b-3
 
Rothenberg Mace over three months ago
Acquisition by Rothenberg Mace of 37500 shares of Tango Therapeutics at 3.51 subject to Rule 16b-3
 
Peters Malte over three months ago
Acquisition by Peters Malte of 6250 shares of Tango Therapeutics subject to Rule 16b-3
 
Borisy Alexis over three months ago
Acquisition by Borisy Alexis of 6250 shares of Tango Therapeutics subject to Rule 16b-3
 
Peters Malte over three months ago
Acquisition by Peters Malte of 37500 shares of Tango Therapeutics at 7.41 subject to Rule 16b-3
 
Weber Barbara over six months ago
Disposition of 9778 shares by Weber Barbara of Tango Therapeutics at 2.988 subject to Rule 16b-3
 
Weber Barbara over six months ago
Disposition of 9013 shares by Weber Barbara of Tango Therapeutics at 3.1614 subject to Rule 16b-3
 
Weber Barbara over six months ago
Disposition of 9778 shares by Weber Barbara of Tango Therapeutics at 2.988 subject to Rule 16b-3
 
Rothenberg Mace over a year ago
Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.78 subject to Rule 16b-3

Tango Therapeutics Corporate Filings

21st of November 2025
Other Reports
ViewVerify
14th of November 2025
Other Reports
ViewVerify
13th of November 2025
Other Reports
ViewVerify
10Q
4th of November 2025
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.